{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:35:19Z","timestamp":1788240919837,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejogrb.2025.114614","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T23:16:13Z","timestamp":1753398973000},"page":"114614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical insights on the complications of TPM use during pregnancy-enabling expectant mothers to make informed choices for their health and the future of their offspring"],"prefix":"10.1016","volume":"313","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-7800","authenticated-orcid":false,"given":"Rajkapoor","family":"Balasubramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswaramurthy","family":"Nallasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina Mohamed","family":"Pakkir Maideen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumarappan","family":"Chidambaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palanisamy","family":"Amirthalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2025.114614_b0005","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114614_b0010","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","article-title":"Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials","volume":"12","author":"Kramer","year":"2011","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.ejogrb.2025.114614_b0015","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","article-title":"Narrative review of topiramate: clinical uses and pharmacological considerations","volume":"40","author":"Pearl","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejogrb.2025.114614_b0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114614_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/138955708783331568","article-title":"Topiramate: its pharmacological properties and therapeutic efficacy in epilepsy","volume":"8","author":"Latini","year":"2008","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.ejogrb.2025.114614_b0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.seizure.2022.03.024","article-title":"Molecular mechanisms of topiramate and its clinical value in epilepsy","volume":"98","author":"Bai","year":"2022","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114614_b0035","doi-asserted-by":"crossref","first-page":"e2290","DOI":"10.1002\/brb3.2290","article-title":"Advances in topiramate as prophylactic treatment for migraine","volume":"11","author":"Hu","year":"2021","journal-title":"Brain and Behavior"},{"issue":"23","key":"10.1016\/j.ejogrb.2025.114614_b0040","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1111\/bph.15657","article-title":"Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments","volume":"178","author":"Zobdeh","year":"2021","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114614_b0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","article-title":"European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention\u2013part 3: topiramate","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"issue":"8","key":"10.1016\/j.ejogrb.2025.114614_b0050","article-title":"The ophthalmic side effects of topiramate: a review","volume":"14","author":"Mechrgui","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ejogrb.2025.114614_b0055","unstructured":"Medicines and Healthcare Products Regulatory Agency. United Kingdom. Drug Safety Update. Topiramate (Topamax): Introduction of new safety measures, including a Pregnancy Prevention Programme. https:\/\/www.gov.uk\/drug-safety-update\/topiramate-topamax-introduction-of-new-safety-measures-including-a-pregnancy-prevention-programme. Published on June 20, 2024. Accessed on June 24, 2024."},{"key":"10.1016\/j.ejogrb.2025.114614_b0060","unstructured":"Medicines and Healthcare Products Regulatory Agency. United Kingdom. Drug Safety Update. Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review. https:\/\/www.gov.uk\/drug-safety-update\/antiepileptic-drugs-in-pregnancy-updated-advice-following-comprehensive-safety-review. Published on Jan 01, 2021. Accessed on July 16, 2024."},{"key":"10.1016\/j.ejogrb.2025.114614_b0065","unstructured":"Medicines and Healthcare Products Regulatory Agency. United Kingdom. Drug Safety Update. Topiramate (Topamax): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure. https:\/\/www.gov.uk\/drug-safety-update\/topiramate-topamax-start-of-safety-review-triggered-by-a-study-reporting-an-increased-risk-of-neurodevelopmental-disabilities-in-children-with-prenatal-exposure. Published on July 21, 2022. Accessed on July 23, 2024."},{"key":"10.1016\/j.ejogrb.2025.114614_b0070","unstructured":"European Medicines Agency. PRAC recommends new measures to avoid topiramate exposure in pregnancy. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/topiramate. Published on October 11, 2023. Accessed on June 18, 2025."},{"key":"10.1016\/j.ejogrb.2025.114614_b0075","unstructured":"Health Sciences Authority. Singapore. Dear Healthcare Professional Letters. TOPAMAX (topiramate) \u2013 Safety measures to prevent exposure during pregnancy. https:\/\/www.hsa.gov.sg\/announcements\/dear-healthcare-professional-letter\/topamax-(topiramate)-safety-measures-to-prevent-exposure-during-pregnancy. Published on November 07, 2024. Accessed on June 18, 2025."},{"key":"10.1016\/j.ejogrb.2025.114614_b0080","unstructured":"National Pharmaceutical Regulatory Agency. Malaysia. [Updated] Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate during Pregnancy. https:\/\/www.npra.gov.my\/index.php\/en\/component\/content\/article\/449-english\/safety-alerts-main\/safety-alerts-2023\/1527474-topiramate-neurodevelopmental-disorders-in-children-exposed-to-topiramate-during-pregnancy.html?Itemid=1391. Published on November 29, 2023. Accessed on June 18, 2025."},{"key":"10.1016\/j.ejogrb.2025.114614_b0085","unstructured":"United States Food and Drug Administration. FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-risk-oral-clefts-children-born-mothers-taking-topamax-topiramate. Updated on February 07, 2018. Accessed on June 18, 2025."},{"key":"10.1016\/j.ejogrb.2025.114614_b0090","unstructured":"Therapeutic Goods Administration. Australia. Medicines Safety Update. Change in the pregnancy category for topiramate. https:\/\/australianprescriber.tg.org.au\/articles\/medicines-safety-update-28.html. Published on April 2012. Accessed on June 18, 2025."},{"issue":"8","key":"10.1016\/j.ejogrb.2025.114614_b0095","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209175","article-title":"Neurodevelopmental and functional outcomes following in utero exposure to antiseizure medication: a systematic review","volume":"102","author":"Honybun","year":"2024","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ejogrb.2025.114614_b0100","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114614_b0105","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jamaneurol.2023.0674","article-title":"Prenatal exposure to antiseizure medication and incidence of childhood-and adolescence-onset psychiatric disorders","volume":"80","author":"Dreier","year":"2023","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0110","article-title":"Specific birth defects following antiseizure medications used by pregnant women with epilepsy","volume":"14","author":"Wiggs","year":"2024","journal-title":"Neurol: Clinical Practice"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0115","first-page":"e27","article-title":"Topiramate ban in women of childbearing potential with idiopathic generalized epilepsy: does effectiveness offset the teratogenic risks?","volume":"65","author":"Cerulli Irelli","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejogrb.2025.114614_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2023.01.008","article-title":"Adaptive behaviour in children exposed to topiramate in the womb: an observational cohort study","volume":"105","author":"Knight","year":"2023","journal-title":"Seizure: Eur J Epilepsy"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114614_b0125","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114614_b0130","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2174\/1570159X19666210716111814","article-title":"Neurodevelopment following exposure to antiseizure medications in utero: a review","volume":"19","author":"Bromley","year":"2021","journal-title":"Curr Neuropharmacol"},{"issue":"24","key":"10.1016\/j.ejogrb.2025.114614_b0135","doi-asserted-by":"crossref","first-page":"e3232","DOI":"10.1212\/WNL.0000000000010993","article-title":"Antiseizure medication use during pregnancy and risk of ASD and ADHD in children","volume":"95","author":"Wiggs","year":"2020","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114614_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.ejogrb.2025.114614_b0145","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","article-title":"In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring","volume":"89","author":"Bech","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ejogrb.2025.114614_b0150","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.seizure.2016.10.006","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes","volume":"44","author":"Bromley","year":"2017","journal-title":"Seizure"},{"issue":"18","key":"10.1016\/j.ejogrb.2025.114614_b0155","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1212\/WNL.0000000000003157","article-title":"Cognition in school-age children exposed to levetiracetam, topiramate, or sodium valproate","volume":"87","author":"Bromley","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114614_b0160","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","volume":"2014","author":"Bromley","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114614_b0165","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/epi.13007","article-title":"Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy","volume":"56","author":"Wood","year":"2015","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0170","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.reprotox.2012.05.038","article-title":"Preliminary findings of the developmental effects of in utero exposure to topiramate","volume":"34","author":"Rihtman","year":"2012","journal-title":"Reprod Toxicol"},{"issue":"2\u20133","key":"10.1016\/j.ejogrb.2025.114614_b0180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eplepsyres.2009.08.004","article-title":"Pharmacokinetics of topiramate during pregnancy","volume":"87","author":"\u00d6hman","year":"2009","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.ejogrb.2025.114614_b0185","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1212\/WNL.0000000000007696","article-title":"Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs","volume":"93","author":"Bloti\u00e8re","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114614_b0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114614_b0195","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eplepsyres.2014.01.021","article-title":"Topiramate monotherapy use in women with and without epilepsy: pregnancy and neonatal outcomes","volume":"108","author":"Castilla-Puentes","year":"2014","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0200","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15513815.2012.659378","article-title":"Multiple fetal anomalies in association with topiramate and oxcarbezepine treatment","volume":"31","author":"Uludag","year":"2012","journal-title":"Fetal Pediatr Pathol"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114614_b0205","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1526-4610.2012.02190.x","article-title":"Utilization of topiramate during pregnancy and risk of birth defects","volume":"52","author":"Green","year":"2012","journal-title":"Headache: J Head Face Pain"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114614_b0210","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.seizure.2009.09.002","article-title":"Population-based study of antiepileptic drug exposure in utero\u2014influence on head circumference in newborns","volume":"18","author":"Almgren","year":"2009","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114614_b0215","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ejogrb.2025.114614_b0220","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/14740338.2021.1943355","article-title":"A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy","volume":"20","author":"Marxer","year":"2021","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114614_b0225","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1212\/WNL.0000000000004857","article-title":"Topiramate use early in pregnancy and the risk of oral clefts: a pregnancy cohort study","volume":"90","author":"Hernandez-Diaz","year":"2018","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114614_b0230","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/pds.3612","article-title":"Topiramate use in pregnancy and the birth prevalence of oral clefts","volume":"23","author":"Mines","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.ejogrb.2025.114614_b0235","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajog.2012.07.008","article-title":"Use of topiramate in pregnancy and risk of oral clefts","volume":"207","author":"Margulis","year":"2012","journal-title":"Am J Obstet Gynecol"},{"issue":"53","key":"10.1016\/j.ejogrb.2025.114614_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reprotox.2015.03.003","article-title":"First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis","volume":"1","author":"Alsaad","year":"2015","journal-title":"Reprod Toxicol"},{"issue":"10","key":"10.1016\/j.ejogrb.2025.114614_b0245","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/pds.3697","article-title":"Evidence accumulates on the association between topiramate use early in pregnancy and the risk of oral clefts","volume":"23","author":"Hernandez-Diaz","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ejogrb.2025.114614_b0250","unstructured":"United States Food and Drug Administration. FDA Drug Safety Communication: FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-risk-oral-clefts-children-born-mothers-taking-topamax-topiramate. Published on April 03, 2011. Accessed on June 25, 2025."},{"issue":"38","key":"10.1016\/j.ejogrb.2025.114614_b0255","article-title":"Prenatal exposure to antiseizure medications and fetal growth: a population-based cohort study from the Nordic countries","volume":"1","author":"Christensen","year":"2024","journal-title":"Lancet Regional Health-Europe"},{"issue":"11","key":"10.1016\/j.ejogrb.2025.114614_b0260","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1111\/epi.12758","article-title":"Birth outcomes after prenatal exposure to antiepileptic drugs\u2014A population\u2010based study","volume":"55","author":"Kilic","year":"2014","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.ejogrb.2025.114614_b0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5698\/1535-7597-14.4.199","article-title":"Topiramate, zonisamide and small for gestational age: maternal factors, timing of exposure and baby fat: TPM, ZNS, and SGA","volume":"14","author":"Harden","year":"2014","journal-title":"Epilepsy Curr"},{"issue":"1","key":"10.1016\/j.ejogrb.2025.114614_b0270","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0000000000000018","article-title":"Association between topiramate and zonisamide use during pregnancy and low birth weight","volume":"123","author":"Hern\u00e1ndez-D\u00edaz","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.ejogrb.2025.114614_b0275","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.reprotox.2008.03.001","article-title":"The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies","volume":"25","author":"Ornoy","year":"2008","journal-title":"Reprod Toxicol"},{"issue":"8","key":"10.1016\/j.ejogrb.2025.114614_b0280","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/bcp.15752","article-title":"Antiseizure medication use during pregnancy and neonatal growth outcomes: a systematic review and meta\u2010analysis","volume":"90","author":"Lavu","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ejogrb.2025.114614_b0285","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1684\/epd.2019.1105","article-title":"Management of epilepsy in pregnancy: a report from the International league against epilepsy task force on women and pregnancy","volume":"21","author":"Tomson","year":"2019","journal-title":"Epileptic Disord"},{"issue":"7","key":"10.1016\/j.ejogrb.2025.114614_b0290","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/10408444.2024.2368552","article-title":"Mechanisms of neurodevelopmental toxicity of topiramate","volume":"54","author":"Steele","year":"2024","journal-title":"Crit Rev Toxicol"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525008905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211525008905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:25:12Z","timestamp":1770985512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211525008905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"alternative-id":["S0301211525008905"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114614","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical insights on the complications of TPM use during pregnancy-enabling expectant mothers to make informed choices for their health and the future of their offspring","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2025.114614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114614"}}